Spire Healthcare Group plc (LON:SPI - Get Free Report) shares were up 14.1% during mid-day trading on Saturday . The company traded as high as GBX 256.50 ($3.46) and last traded at GBX 247 ($3.33). Approximately 9,747,062 shares traded hands during mid-day trading, an increase of 563% from the average daily volume of 1,469,073 shares. The stock had previously closed at GBX 216.50 ($2.92).
Analyst Upgrades and Downgrades
Several equities research analysts have recently issued reports on the company. JPMorgan Chase & Co. decreased their target price on Spire Healthcare Group from GBX 309 to GBX 303 and set an "overweight" rating for the company in a research report on Tuesday, August 5th. Berenberg Bank reaffirmed a "buy" rating and issued a GBX 280 price target on shares of Spire Healthcare Group in a research note on Thursday, July 31st. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of GBX 294.33.
Check Out Our Latest Report on SPI
Spire Healthcare Group Trading Up 14.1%
The company has a debt-to-equity ratio of 62.25, a quick ratio of 0.74 and a current ratio of 0.70. The stock has a market cap of £993.86 million, a PE ratio of 5,369.57, a PEG ratio of 1.06 and a beta of 0.96. The stock has a fifty day moving average price of GBX 218.75 and a 200 day moving average price of GBX 203.41.
Spire Healthcare Group (LON:SPI - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported GBX 4.10 EPS for the quarter. Spire Healthcare Group had a return on equity of 3.82% and a net margin of 1.96%. Equities analysts expect that Spire Healthcare Group plc will post 15.6634747 EPS for the current year.
About Spire Healthcare Group
(
Get Free Report)
Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.
Further Reading
Before you consider Spire Healthcare Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spire Healthcare Group wasn't on the list.
While Spire Healthcare Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.